1114544-31-8

1114544-31-8 structure

Name: Ponatinib hydrochloride
Chemical Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide,hydrochloride
CAS Number: 1114544-31-8
Molecular Formula: C₂₉H₂₈ClF₃N₆O
Molecular Weight: 569.02
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2018-08-27 11:47:54
Modify Date: 2026-07-02 13:14:20
Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].

Name	3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide,hydrochloride
Synonyms	Ponatinib (HCl salt) 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride Ponatinib-HCl buscamos el HCl Ponatinib hydrochloride (USAN) AP24534-HCl Ponatinib hydrocholoride Ponatinib Hyd 96R6PU3D8J Ponatinib HCl 3-(Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride (1:1) Mercaptopurine Impurity C2,15N AP24534 Mono-hydrochloride 3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl)benzamide hydrochloride Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-, hydrochloride (1:1) Iclusig (TN) UNII-96R6PU3D8J Ponatinib HCl/1114-8 AP 24534 hydrochloride Ponatinib Mono-hydrochloride

Description	Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
Target	VEGFR2:1.5 nM (IC50) FGFR1:2.2 nM (IC50) PDGFRα:1.1 nM (IC50) Abl:0.37 nM (IC50) LYN:0.24 nM (IC50) Src:5.4 nM (IC50)
References	[1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.

Hazard Codes	Xn